The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,174,016 in first-year total cost, median $1,587,008.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BN-M (91)]2
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- UNIVERSITY OF CALIFORNIA-IRVINE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Adverse Cerebrovascular Responses to Antibodies Targeting Beta-Amyloid1RF1NS134046-01A1 | CRIBBS, DAVID HASTINGS | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $2,342,415 | ZRG1 |
| 2024 | Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid Immunotherapy1R01NS136122-01 | LEMERE, CYNTHIA A | BRIGHAM AND WOMEN'S HOSPITAL, MA | $831,601 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.